Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Co2Bioclean GmbH currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct art unit, showing a specific technical focus for the company's current patent activities. Navigating a single art unit allows the applicant to tailor its legal arguments to the specific standards and precedents common within that specialized biotechnology group.
The busiest examiner for the portfolio is KIEFER, DALTON EDWARD, who is handling the 1 pending office action. With only 1 distinct examiner involved, the company's prosecution success is currently tied to the evaluation of this single individual. This concentration of work under KIEFER, DALTON EDWARD simplifies the communication process between the applicant and the patent office by centralizing all active discussions.
Because there is only 1 pending office action, the overall health of the portfolio's current prosecution phase depends on the resolution of this 1 case. The 1 distinct art unit involved provides a stable environment for the application, as the company does not need to account for the varying procedural styles of multiple administrative divisions. This focused approach is characteristic of a portfolio with a single active matter in the biotechnology sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KIEFER, DALTON EDWARD | 1 | 85.7% | +16.7% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18570699 | Production of Biopolymers | KIEFER, DALTON EDWARD | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18570699 | Production of Biopolymers | KIEFER, DALTON EDWARD | — |
| Art Unit | Apps |
|---|---|
| 1652 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18570699 | Production of Biopolymers | KIEFER, DALTON EDWARD | 1652 | §103DP | Non-Final OA | — | Pending | Dec 15, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCo2Bioclean GmbH has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Dalton Edward Kiefer has the most, with 1 of Co2Bioclean GmbH's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
